Literature DB >> 26405337

Simvastatin: Multiple Sclerosis.

Joyce A Generali1, Dennis J Cada2.   

Abstract

This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.

Entities:  

Year:  2015        PMID: 26405337      PMCID: PMC4568106          DOI: 10.1310/hpj5006-464

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  7 in total

Review 1.  Statins for multiple sclerosis.

Authors:  Jin Wang; Yousheng Xiao; Man Luo; Hongye Luo
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

Review 2.  Efficacy of statins in combination with interferon therapy in multiple sclerosis: a meta-analysis.

Authors:  Shilpa Bhardwaj; Craig I Coleman; Diana M Sobieraj
Journal:  Am J Health Syst Pharm       Date:  2012-09-01       Impact factor: 2.637

3.  Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.

Authors:  Mansoureh Togha; Sanaz Ahmadi Karvigh; Masoud Nabavi; Nahid Beladi Moghadam; Mohammad Hossein Harirchian; Mohammad Ali Sahraian; Anahita Enzevaei; Alireza Nourian; Hossein Ghanaati; Kavous Firouznia; Ali Jannati; Majid Shekiba
Journal:  Mult Scler       Date:  2010-05-20       Impact factor: 6.312

4.  Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.

Authors:  Per Soelberg Sorensen; Jan Lycke; Juha-Pekka Erälinna; Astrid Edland; Xingchen Wu; Jette Lautrup Frederiksen; Annette Oturai; Clas Malmeström; Egon Stenager; Finn Sellebjerg; Helle Bach Sondergaard
Journal:  Lancet Neurol       Date:  2011-08       Impact factor: 44.182

5.  Statins as immunomodulators: comparison with interferon-beta 1b in MS.

Authors:  O Neuhaus; S Strasser-Fuchs; F Fazekas; B C Kieseier; G Niederwieser; H P Hartung; J J Archelos
Journal:  Neurology       Date:  2002-10-08       Impact factor: 9.910

Review 6.  Statins as potential therapeutic agents in neuroinflammatory disorders.

Authors:  Olaf Stüve; Sawsan Youssef; Lawrence Steinman; Scott S Zamvil
Journal:  Curr Opin Neurol       Date:  2003-06       Impact factor: 5.710

7.  Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients.

Authors:  C E Teunissen; C D Dijkstra; C H Polman; E L J Hoogervorst; K von Bergmann; D Lütjohann
Journal:  Neurosci Lett       Date:  2003-08-28       Impact factor: 3.046

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.